A61K 47/642
The peptide or protein in the drug conjugate being a cytokine
Official title: {the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate}
A61K47/642 (The peptide or protein in the drug conjugate being a cytokine) appears on 327 US grants and 489 published applications in this corpus.
Search patents in A61K- Granted patents
- 327
- Published applications
- 489
- Assignees
- 276
- Inventors
- 729
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 7 | 0 |
| 1998 | 4 | 0 |
| 1999 | 5 | 0 |
| 2000 | 7 | 0 |
| 2001 | 3 | 2 |
| 2002 | 9 | 10 |
| 2003 | 8 | 28 |
| 2004 | 6 | 15 |
| 2005 | 3 | 21 |
| 2006 | 15 | 19 |
| 2007 | 12 | 13 |
| 2008 | 13 | 19 |
| 2009 | 8 | 19 |
| 2010 | 15 | 17 |
| 2011 | 7 | 20 |
| 2012 | 7 | 6 |
| 2013 | 9 | 13 |
| 2014 | 11 | 18 |
| 2015 | 12 | 18 |
| 2016 | 9 | 21 |
| 2017 | 24 | 21 |
| 2018 | 7 | 19 |
| 2019 | 16 | 27 |
| 2020 | 17 | 15 |
| 2021 | 17 | 22 |
| 2022 | 7 | 39 |
| 2023 | 14 | 23 |
| 2024 | 9 | 29 |
| 2025 | 17 | 20 |
| 2026 | 15 | 15 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment of immunosuppressed subjects15 Sep 2026US 12,734,216 B2NantCell, Inc.
- Compositions and methods for inhibiting the biological activity of soluble biomolecules21 Jul 2026US 12,685,758 B2NaNotics, LLC
- Interleukin-18 variants and methods of use21 Jul 2026US 12,685,759 B2Yale University
- Gla domains as therapeutic agents14 Jul 2026US 12,678,481 B2Gladiator Biosciences, Inc.
- Composition for preventing or treating cancer, containing IL-2 surface expression-extracellular vesicles as active ingredient7 Jul 2026US 12,673,114 B2Daegu Gyeongbuk Institute of Science and Technology
- A proimmunotoxin therapeutic nanoplatform against cancer8 Oct 2026US 2026/0308268 A1The Regents of the University of California
- Multi-target drug conjugate and use thereof for cancer treatment1 Oct 2026US 2026/0295061 A1Virginia Tech Intellectual Properties, Inc.
- Use of immunomodulation methods in combination with cytokine fusions for disease treatment13 Aug 2026US 2026/0232820 A1Medicenna Therapeutics Inc.
- Insulin-like growth factor-chemotherapeutic conjugate for treating myelodysplastic syndrome23 Jul 2026US 2026/0207757 A1IGF Oncology, LLC
- Scaffold proteins and therapeutic nanoconjugates based on nidogen2 Jul 2026US 2026/0184764 A1Consorcio Centro De InvestigacióN BioméDica En Red
Most cited
By later US patents
- Cytotoxic drug conjugates and their delivery to tumor cells271US 5,087,616 ABattelle Memorial Institute · 1992
- Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease256US 7,659,241 B2Seattle Genetics, Inc. · 2010
- Immunoglobulin chimeric monomer-dimer hybrids215US 7,404,956 B2Syntonix Pharmaceuticals, Inc. · 2008
- Fusion polypeptides comprising human serum albumin, nucleic acids encoding same, and recombinant expression thereof208US 5,876,969 A1999
- Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells200US 6,653,104 B2Immunomedics, Inc. · 2003